FGFR2 and non-small cell lung carcinoma: For instance, Qin et al. [19] reported FGFR fusions retaining the kinase domain in 0.2% (52 of 26.054 NSCLC cases), including 37 FGFR3-TACC3 fusions, two FGFR2 fusions, one FGFR1 fusion (all previously reported), and 12 novel FGFR1, FGFR2, FGFR3, and FGFR4 fusions.